FRANKFURT/TAIPEI (Reuters) - AstraZeneca’s coronavirus vaccine received a major boost on Monday after data from a large trial showed it was safe and effective, potentially paving the way for its emergency authorisation in the United States as countries in Asia accelerated its rollout.
The trials in the United States, Chile and Peru showed the vaccine was 79% effective at preventing symptomatic COVID-19 and could bolster confidence in the product after confusion over its efficacy data, dosing regimen and possible side-effects.
Lo zio Sam approva.